Registered number: 8999695

ACME PHARMA LTD UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2017

ACME PHARMA LTD Unaudited Financial Statements For The Year Ended 31 March 2017

Contents

	Page
Balance Sheet	1-2
Statement of Changes in Equity	3
Notes to the Financial Statements	4—6

ACME PHARMA LTD Balance Sheet As at 31 March 2017

Registered number: 8999695

		2017		2016	
	Notes	£	£	£	£
FIXED ASSETS					
Tangible Assets	6	_	2,459	_	1,485
			2,459		1,485
CURRENT ASSETS					
Debtors	7	268,851		186,789	
Cash at bank and in hand		387,182	_	257,233	
		656,033		444,022	
Creditors: Amounts Falling Due Within One Year	8	(230,615)	-	(243,084)	
NET CURRENT ASSETS (LIABILITIES)			425,418	-	200,938
TOTAL ASSETS LESS CURRENT LIABILITIES			427,877		202,423
Creditors: Amounts Falling Due After More Than One Year	9		(200,000)	-	(106,197)
NET ASSETS		_	227,877	_	96,226
CAPITAL AND RESERVES		•		-	
Called up share capital	10		10		10
Profit and loss account		_	227,867	_	96,216
SHAREHOLDERS' FUNDS			227,877		96,226

ACME PHARMA LTD Balance Sheet (continued) As at 31 March 2017

For the year ending 31 March 2017 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities

- The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
- The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
- These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.

On behalf of the board

Ms RINKLE BUDDHADEV

24/04/2017

The notes on pages 4 to 6 form part of these financial statements.

ACME PHARMA LTD Statement of Changes in Equity For The Year Ended 31 March 2017

	Share Capital	Profit & Loss Account	Total
	£	£	£
As at 1 April 2015	10	75	85
Profit for the year and total comprehensive income	-	102,338	102,338
Dividends paid	_	(6,197)	(6,197)
As at 31 March 2016 and 1 April 2016	10	96,216	96,226
Profit for the year and total comprehensive income		158,075	158,075
Dividends paid		(26,424)	(26,424)
As at 31 March 2017	10	227,867	227,877

ACME PHARMA LTD Notes to the Unaudited Accounts For The Year Ended 31 March 2017

1. Accounting Policies

1.1. Basis of Preparation of Financial Statements

The financial statements are prepared under the historical cost convention and in accordance with the FRS 102 Section 1A Small Entities - The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.

1.2. Turnover

Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.

1.3. Tangible Fixed Assets and Depreciation

Tangible fixed assets are stated at cost less depreciation. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Fixtures & Fittings 25 Computer Equipment 25

1.4. Registrar Filing Requirements

The company has taken advantage of Companies Act 2006 section 444(1) and opted not to file the profit and loss account, directors report, and notes to the financial statements relating to the profit and loss account. The notes which are not included have been hidden but original note numbering has remained the same for those that are present.

3. Staff Costs

Staff costs, including directors' remuneration, were as follows:

	2017	2016
	£	£
Wages and salaries	47,436	44,164
Social security costs	326	1,801
	47,762	45,965

4. Average number of employees

Average number of employees, including directors, during the year was as follows:

	2017	2010
Office and administration	1	-
Sales, marketing and distribution	2	-
	3	

2016

2017

ACME PHARMA LTD

Notes to the Unaudited Accounts (continued) For The Year Ended 31 March 2017

6. Tangible Assets

Cost		£
Cost		
As at 1 April 2016		1,980
Additions		1,957
As at 31 March 2017		3,937
Depreciation		
As at 1 April 2016		495
Provided during the period		983
As at 31 March 2017		1,478
Net Book Value		
As at 31 March 2017		2,459
As at 1 April 2016		1,485
7. Debtors		2016
	2017	2016
	£	£
Due within one year		
Trade debtors	-	60,466
Other debtors Rent Deposit	- 10,502	259 10,502
VAT	258,349	115,562
VAI		
	268,851	186,789
8. Creditors: Amounts Falling Due Within One Year	2017	2016
	2017	2016
₹ . d dr	£	£
Trade creditors Bank loans and overdrafts	26,383 458	44,807
Corporation tax	39,765	2E 212
Other taxes and social security	663	25,213
Net wages	5,778	690
Other Creditors-Unpaid Dividend	19,421	- 090
Astute Health care Ltd	135,891	169,359
SMART CURRENCY	(259)	-,
Accruals and deferred income	2,515	3,015
	230,615	243,084

ACME PHARMA LTD Notes to the Unaudited Accounts (continued)

For The Year Ended 31 March 2017

9.	Creditors:	Amounts	Falling	Due After	More	Than	One Year	
----	------------	----------------	---------	------------------	------	------	----------	--

	2017	2016
	£	£
Directors loan account	200,000	106,197

Directors Loan is from Ms Rinkle Rameshkumar Buddhadev. The loan is interest free unsecured and subordinated in fravour of third party creditors

10. Share Capital

	Value	Number	2017	2016
Allotted, called up and fully paid	£		£	£
Ordinary shares	10.000	1	10	10

11. Transactions With and Loans to Directors

Dividends paid to directors

12. Dividends

	2017	2016
	£	£
On equity shares:		
Final dividend paid	26,424	6,197
_	26,424	6,197

13. Ultimate Controlling Party

The company's ultimate controlling party is by virtue of his ownership of 100% of the issued share capital in the company.

14. General Information

ACME PHARMA LTD Registered number 8999695 is a limited by shares company incorporated in England & Wales. The Registered Office is 337, ATHLON ROAD, WEMBLEY, HAO 1EF.

lectronic form, authenticat	ion and maimer or d	envery under section	n 1072 or the Compa	illes Act 2006.	